Table 1. Summary of patients per risk group.
| Total | Low Risk: 10 Normal-like, 11 LumA |
High Risk: 22 LumB, 11 HER2+, 17 Basal-like |
p for Difference |
|
|---|---|---|---|---|
| No. of patients | 71 (100) | 21 (29.5) | 50 (70.4) | 0.0004 |
| Avg. age | 50.8 | 51.5 | 50.5 | 0.7095 |
| Age < 50 | 33 (46) | 9 (42.8) | 24 (48.0) | 0.7965 |
| Menopausal status | 0.7965 | |||
| Pre-menopausal | 33 (47.8) | 9 (45.0) | 24 (49.0) | |
| Post-menopausal | 36 (52.2) | 11 (55.0) | 25 (51.0) | |
| Histological grade | 1.0000 | |||
| 1-Well differentiated | 6 (8.5) | 2 (9.5) | 4 (8.0) | |
| 2-Moderatly diff. | 37 (52.1) | 11 (52.4) | 26 (52.0) | |
| 3-Poorly diff. | 23 (32.4) | 7 (33.3) | 16 (32.0) | |
| NA | 5 (7.0) | 1 (4.8) | 4 (8.0) | |
| Tumor size | 0.3280 | |||
| T1 (< = 20 mm) | 8 (11.3) | 4 (19.1) | 4 (8.0) | |
| T2 (21–50 mm) | 44 (62.0) | 12 (57.1) | 32 (64.0) | |
| T3 (>50 mm) | 18 (26.8) | 4 (19.1) | 14 (28.0) | |
| Node status | 1.0000 | |||
| N0 | 13 (18.3) | 4 (19.0) | 9 (18.0) | |
| N1 | 31 (43.7) | 9 (42.6) | 22 (44.0) | |
| N2 | 24 (33.8) | 7 (33.3) | 17 (34.0) | |
| N3 | 2 (2.8) | 0 | 2 (4.0) | |
| Metastasis status | 1.0000* | |||
| M0 | 63 (88.7) | 19 (90.5) | 44 (88.0) | |
| M1 | 5 (7.0) | 1 (4.8) | 4 (8.0) | |
| Mx | 3 (4.2) | 0 | 2 (4.0) | |
| Immunohistochemical | 0.0169* | |||
| HR+ (ER / PR), HER2- | 35 (49.3) | 13 (61.9) | 22 (44.0) | |
| HR- (ER & PR), HER2+ | 13 (18.3) | 6 (28.6) | 7 (14.0) | |
| HR+ (ER / PR), HER2+ | 5 (7.0) | 0 | 5 (10.0) | |
| HR- (ER & PR), HER2- (TN) | 17 (23.9) | 1 (4.8) | 16 (32.0) | |
| (NA) | 1 (1.4) | 1 (4.8) | 0 |
For patient counts, numbers in parenthesis represent percentages. LumA = luminal A, LumB = luminal B, HR = Hormone Receptors, ER = Estrogen Receptor, PR = Progesterone Receptor, TN = Triple Negative. Numbers represent only those patients with available information.
* Removing (NA) or Mx.